The effect of extended release tolterodine used for overactive bladder treatment on female sexual function

Zachariou, Athanasios; Filiponi, Μaria

doi:10.1590/s1677-5538.ibju.2016.0303

Cited by 14 publications

(8 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FSFI is one of the most frequently adopted questionnaires in assessing female sexual function and dysfunction, and it has been strongly recommended from the latest report of International Consultation on Sexual Medicine. [14, 15] FSFI allows to study and classify the following domains: (a) desire (b) arousal (c) lubrication (d) orgasm (e) satisfaction and (f) pain. A total FSFI score of 26.5 is the cut-off to discriminate women with and without sexual dysfunction [16].…”

Section: Methodsmentioning

confidence: 99%

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder

et al. 2019

View full text Add to dashboard Cite

BackgroundOveractive bladder (OAB) can frequently exert a negative effect on female sexual function. Mirabegron, a β3 receptor agonist, improves OAB symptoms, but there are very few information about its role on female sexual dysfunction (FSD). Aim of the study was to assess the impact of Mirabegron on FSD in women affected by OAB.MethodsFifty sexually active women suffering from idiopathic OAB were included in the study. Patients were assessed by means of a urogynecologic physical examination and were asked to complete the 3-day voiding diary, the International Consultation on Incontinence Questionnaire- Short Form (ICIQ-SF), the Female Sexual Function Index (FSFI) questionnaire and VAS, before and 12 weeks after treatment with Mirabegron. In addition, at the same time points, patients underwent uroflowmetry with the measurement of post- void residual volume (PVR).ResultsAt baseline all patients were affected by OAB symptoms, with 49/50 patients (98%) presenting with FSD. At 12- weeks follow- up, OAB symptoms improved significantly in all patients, with 59.5% of subjects achieving a complete urinary continence. FSFI Total Score significantly improved in 42/50 patients (84%) from 18.9 ± 4.3 to 21.8 ± 4.5 (p < 0.0001). Sixteen cases (32%) presented with no FSD. Also mean ± SD scores of ICIQ-SF and VAS significantly improved (from 17.1 ± 5 to 7.9 ± 4.8 and from 3.9 ± 1.2 to 6.9 ± 1.2 respectively, p < 0.000).ConclusionsMirabegron not only is able to control urinary symptoms in women with OAB, but also induces a significant improvement in their sexual life.

show abstract

Section: Methodsmentioning

confidence: 99%

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Overall FSFI scores were higher in the group that received tolterodine. 21 An older study from 2008 illustrated similar findings with tolterodine. 16 Hajebrahimi et al 16 followed 30 sexually active women with OAB from ages 20e52 years by using the Arizona Sexual Experience Scale (ASEX) before treatment with tolterodine and at the end of each month of treatment until 3 months.…”

Section: Pharmacotherapy Effect On Sexual Functionmentioning

confidence: 73%

“…This review shed light on a handful of small trials, with inconsistent outcome measures, and concluded with no standard recommendation. 20 A study by Zachariou et al 21 demonstrated that PFMT improved sexual function in women with stress urinary incontinence by using FSFI scores before and after therapy. Although the study focused on patients with SUI and not OAB, it showed that improvement in urinary incontinence symptoms after PFMT can improve sexual function.…”

Section: Conservative Treatment: Pelvic Floor Physiotherapy and Its Ementioning

confidence: 99%

“…They were re-evaluated after 3 months: 70% of the patients described improvement in sexual function (by using FSFI questionnaires). 26 Another study that investigated the effects of tolterodine on sexual function was carried out by Zachario and Filiponi, 21 who studied 158 women with OAB. They divided their study population into 2 groups: 1 group received tolterodine, and the other group received no treatment.…”

Section: Pharmacotherapy Effect On Sexual Functionmentioning

confidence: 99%

See 1 more Smart Citation

Overactive Bladder Syndrome Treatments and Their Effect on Female Sexual Function: A Review

Levy

Löwenstein

2019

Sexual Medicine

View full text Add to dashboard Cite

Introduction: Overactive bladder (OAB), the most common subtype of urinary incontinence, has a heavy price on quality of life, especially on sexual life. Unfortunately, most women rarely voice the worsening of sexual function, especially those who already suffer from OAB symptoms. It has been demonstrated that patients who suffer from OAB score lower on Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire and Female Sexual Function Index scores, meaning that their sexual function is debilitated. Therapies for OAB begin with traditional pelvic floor physiotherapy, advance to anticholinergic drugs, and become more invasive with intravesical injections of onabotulinumtoxinA (commonly known as Botox). Last, for patients resistant to conservative therapies, sacral neuromodulation is the treatment of choice. Methods: This article reviews the current literature that sheds light on the above 4 treatments and their effect on sexual function. This topic is of great importance because of the under-reporting of sexual dysfunction in women who suffer from OAB, in hopes of raising awareness of sexual function for clinicians treating patients with OAB. Results: This review found that the aforementioned 4 treatments for OAB (physiotherapy, anticholinergic drugs, intravesical injections of onabotulinumtoxinA, and sacral neuromodulation) do not have a detrimental affect on sexual function. On the contrary, the little data that do exist show that sexual function increases after these therapies are completed in women with OAB. Conclusion: This review concludes with a positive outlook: physicians are helping women with OAB syndrome to improve their sexual function. However, not enough data exist, partially due to under-reporting of diminished sexual function.

show abstract

“…[12][13][14][15] There is a higher rate of sexual dysfunction in OAB with urinary incontinence (OAB-wet) than in OAB-dry, and sexual dysfunction improves with treatment for OAB. [16][17][18][19] Stress urinary incontinence is strongly involved in urinary incontinence during sexual intercourse, with reduced urethral resistance contributing the most. [20][21][22][23] In surgery for stress urinary incontinence and pelvic organ prolapse, it has been reported that, while it improves sexual function, there is apprehension that transvaginal mesh implantation can cause dyspareunia (coital pain) and chronic pain.…”

Section: Selected Cqsmentioning

confidence: 99%

Clinical Guidelines for Female Lower Urinary Tract Symptoms (second edition)

Takahashi¹,

Takei²,

Asakura³

et al. 2021

Int J of Urology

View full text Add to dashboard Cite

The present article is an abridged English translation of the Japanese Clinical Guidelines for Female Lower Urinary Tract Symptoms (second edition), published in September 2019. These guidelines consist of a total of 212 pages and are unique worldwide in that they cover female lower urinary tract symptoms other than urinary incontinence. They contain two algorithms for "primary treatment" and "specialized treatment," respectively. These guidelines, consisting of six chapters, address a total of 26 clinical questions including: (i) treatment algorithms; (ii) what are female lower urinary tract symptoms?; (iii) epidemiology and quality of life; (iv) pathology and illness; (v) diagnosis; and (vi) treatment. When the patient's symptoms mainly involve voiding and post-micturition symptoms, specialized treatment should be considered. In the event of voiding symptoms concurrent with storage symptoms, residual urine should be measured; if the residual urine volume is <100 mL, then diagnosis and treatment for storage symptoms is prioritized, and if the volume is ≥100 mL, then specialized treatment should be considered. When storage symptoms are the primary condition, then the patient is subject to the primary treatment algorithm. Specialized treatment for refractory overactive bladder includes botulinum toxin injection and sacral nerve stimulation. For stress urinary incontinence, surgical treatment is indicated, such as urethral slings. The two causes of voiding symptoms and post-micturition symptoms are lower urinary tract obstruction and detrusor underactivity (underactive bladder). Mechanical lower urinary tract obstruction, such as pelvic organ prolapse, is expected to improve with surgery.

show abstract

The effect of extended release tolterodine used for overactive bladder treatment on female sexual function

Cited by 14 publications

References 28 publications

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder

Overactive Bladder Syndrome Treatments and Their Effect on Female Sexual Function: A Review

Clinical Guidelines for Female Lower Urinary Tract Symptoms (second edition)

Contact Info

Product

Resources

About